Volume 19, Issue 2 (Scientific Journal of Hamadan University of Medical Sciences-Summer 2012)                   Avicenna J Clin Med 2012, 19(2): 34-38 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Abdoli E, Rastgoo Haghi A, Torabian S. Expression of Cyclooxygenase 2 and p-53 and their Relation with 5 Years Survival in Hodgkin's Lymphoma. Avicenna J Clin Med 2012; 19 (2) :34-38
URL: http://sjh.umsha.ac.ir/article-1-187-en.html
1- , e_abdoli90@yahoo.com
Abstract:   (4278 Views)

Introduction & Objective: Hodgkin lymphoma accounts for about 1% of all cancers. Cyclooxygenase 2 (COX2) is a cytoplasmic enzyme. Oncogene, and growth factor induce over expression of COX2. COX2 is apoptotic inhibitor. Mutation of the p53 tumor suppressor gene represents the most common genetic alternation in human tumors. This study aimed to evaluate the expression of COX2 and p53 in subtypes of Hodgkin's lymphoma.

Materials & Methods: In this cross- sectional study,62 Hodgkin's lymphomas were studied in admitted samples of pathology departments of Hamadan hospitals before 2005.Age,sex and type of HL were recorded in each case. p53 and COX2 expression was investigated immunohistochemically and expression intensity. The comparison of p53 and COX2 between subtypes of HL was evaluated with SPSS v13 soft ware and chi-square test.

Results: The mean age of the patients of HL was 41±16 and 79% if HL immunoreactive for p53. In this study the mean age of the patients of HL who died was more than the mean age of the patients of HL who survived which is statistically considered significant (P<0.003). 24% of the patients of HL were immunoreactive for COX2.

Conclusion: Regarding to p53 and COX2 in subtypes of HL and insignificant difference in p53 and COX2 expression between subtypes of HL. We concluded that p53 and COX2 have not an important role in the prognosis of HL, but it is recommended to do more universal studies in the immunohistochemical level of P53 and COX2 to attain perfect results.

Full-Text [PDF 203 kb]   (3857 Downloads)    
Type of Study: Original | Subject: Other Clinical Specialties

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Avicenna Journal of Clinical Medicine

Designed & Developed by : Yektaweb